Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Pinterest Inc (PINS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Pinterest Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Pinterest Inc trades at $22.16 (market cap $12.56B). The key difference: Pinterest Inc is far larger — about 2.8× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | PINS | |
|---|---|---|
Market Cap | $4.49B | $12.56B |
Sector | Health | Media |
52-Week High | $28.06 | $39.17 |
52-Week Low | $20.06 | $15.42 |
Enterprise Value | $3.69B | $12.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Pinterest (PINS) trades at $22.42, up 1.59% with a bullish technical outlook. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin declined to 7.64% in 2026. Recent AI shopping initiatives and Amazon integration highlight strategic moves to boost monetization. Analyst consensus is bullish with a $27.82 price target, representing 24% upside potential from current levels.
PINS presents a growth opportunity with improving fundamentals and strong analyst support, but faces execution risks in monetizing its user base. The stock's elevated P/E ratio of 46.35 requires sustained earnings growth to justify valuation. Competitive pressures in social media and dependency on advertising revenue remain key challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
